Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
R-pola-mini-CHP · 1 trial · 2 indications
Interval between randomization date and date of documented progression, first relapse, or death of any cause
| Arm | Type | Description |
|---|---|---|
| Arm A - R-mini-CHOP | ACTIVE_COMPARATOR | Cycles 1-6, duration 21 days * Rituximab 375 mg/m2 i.v., day 1, cycle 1. 1400 mg s c OR 375 mg/m2 i. v. cycles 2-6 * Cyclophosphamide 400 mg/m2 i.v., day 1, cycles 1-6 * Doxorubicin 25 mg/m2 i.v., day 1, cycles 1-6 * Vincristine 1 mg i.v. (total dose), day 1, cycles 1-6 * Prednisone, 40 mg/m2 p.o, days 1-5, , cycles 1-6 |
| Arm B - R-pola-mini-CHP | EXPERIMENTAL | Cycles 1-6, duration 21 days * Rituximab 375 mg/m2 i.v., day 1, cycle 1. 1400 mg s c OR 375 mg/m2 i. v. cycles 2-6 * Cyclophosphamide 400 mg/m2 i.v., day 1, cycles 1-6 * Doxorubicin 25 mg/m2 i.v., day 1, cycles 1-6 * Prednisone, 40 mg/m2 p.o, days 1-5, , cycles 1-6 * Polatuzumab vedotin 1.8 mg/kg i.v day 1 cycles 1-6 |
| Name | Type | Description |
|---|---|---|
| R-pola-mini-CHP | DRUG | * Rituximab 375 mg/m2 iv, day 1, cycle 1. 1400 mg s c OR 375 mg/m2 iv cycles 2-6 * Cyclophosphamide 400 mg/m2 iv, day 1, cycles 1-6 * Doxorubicin 25 mg/m2 iv , day 1, cycles 1-6 * Prednisone, 40 mg/m2 po, days 1-5, cycles 1-6 - round up to nearest 25 mg * Polatuzumab vedotin 1.8 mg/kg iv day 1 cycles 1-6 |
| R-mini-CHOP | DRUG | * Rituximab 375 mg/m2 i.v., day 1, cycle 1. 1400 mg s c OR 375 mg/m2 i. v. cycles 2-6 * Cyclophosphamide 400 mg/m2 i.v., day 1, cycles 1-6 * Doxorubicin 25 mg/m2 i.v., day 1, cycles 1-6 * Vincristine 1 mg i.v. (total dose), day 1, cycles 1-6 * Prednisone, 40 mg/m2 p.o, days 1-5, , cycles 1-6 |
Inclusion Criteria: * Age ≥80 years or frail ≥75 years, according to simplified comprehensive geriatric assessment * Histologically confirmed lymphoma belonging to one of the following subtypes: 1. diffuse large B-cell lymphoma, including transformation from an indolent lymphoma 2. follicular ...
R-pola-mini-CHP is an investigational combination regimen being studied for diffuse large B cell lymphoma (DLBCL). It pairs polatuzumab vedotin with reduced-intensity CHP chemotherapy, a lower-dose backbone designed for older patients. It is being developed by Roche Holding AG (ticker RHHBY) and is currently in Phase 3 clinical development.
R-pola-mini-CHP is being evaluated for the treatment of diffuse large B cell lymphoma (DLBCL), including diffuse large B cell lymphoma, in patients aged 75 years and older. The regimen is intended as a reduced-intensity option for this older population, and it remains investigational rather than approved.
Roche Holding AG, which trades under the ticker RHHBY, is the developer of R-pola-mini-CHP. The regimen combines polatuzumab vedotin, a Roche asset, with reduced-intensity CHP chemotherapy. Roche is running the clinical program evaluating this combination in diffuse large B cell lymphoma.
R-pola-mini-CHP is in Phase 3 development. It is investigational and has not been approved by the FDA. The ongoing study is a randomized, active-controlled Phase 3 trial, and no trials of this regimen have been completed to date.
R-pola-mini-CHP is being studied in the Phase 3 trial NCT04332822, titled a randomized, multicenter Phase III trial comparing R-mini-CHOP with R-mini-CHP plus polatuzumab vedotin in patients with diffuse large B cell lymphoma. The trial is recruiting, targets 300 patients, and enrolls participants aged 75 years and older across Australia, Denmark, Finland, Italy, New Zealand, Norway, and Sweden.
Yes. The R-pola-mini-CHP Phase 3 trial NCT04332822 is biomarker selected, meaning enrollment is guided by a biomarker. The study is randomized and active-controlled, comparing the polatuzumab vedotin plus reduced-intensity CHP regimen against R-mini-CHOP in patients with diffuse large B cell lymphoma aged 75 years and older.